| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Richard E Daws, Christopher Timmermann, Bruna Giribaldi, James D Sexton, Matthew B Wall, David Erritzoe, Leor Roseman, David Nutt, Robin Carhart-Harri. Increased global integration in the brain after psilocybin therapy for depression. Nature medicine. 2022-04-12. PMID:35411074. |
increased global integration in the brain after psilocybin therapy for depression. |
2022-04-12 |
2023-08-13 |
Not clear |
| Richard E Daws, Christopher Timmermann, Bruna Giribaldi, James D Sexton, Matthew B Wall, David Erritzoe, Leor Roseman, David Nutt, Robin Carhart-Harri. Increased global integration in the brain after psilocybin therapy for depression. Nature medicine. 2022-04-12. PMID:35411074. |
we assessed the subacute impact of psilocybin on brain function in two clinical trials of depression. |
2022-04-12 |
2023-08-13 |
Not clear |
| Richard E Daws, Christopher Timmermann, Bruna Giribaldi, James D Sexton, Matthew B Wall, David Erritzoe, Leor Roseman, David Nutt, Robin Carhart-Harri. Increased global integration in the brain after psilocybin therapy for depression. Nature medicine. 2022-04-12. PMID:35411074. |
the first was an open-label trial of orally administered psilocybin (10 mg and 25 mg, 7 d apart) in patients with treatment-resistant depression. |
2022-04-12 |
2023-08-13 |
Not clear |
| Psilocybin increases brain network integration in patients with depression. Nature medicine. 2022-04-12. PMID:35411079. |
psilocybin increases brain network integration in patients with depression. |
2022-04-12 |
2023-08-13 |
Not clear |
| Mitch Earleywine, Fiona Low, Brianna R Altman, Joseph De Le. How Important Is a Guide Who Has Taken Psilocybin in Psilocybin-Assisted Therapy for Depression? Journal of psychoactive drugs. 2022-03-23. PMID:35318904. |
how important is a guide who has taken psilocybin in psilocybin-assisted therapy for depression? |
2022-03-23 |
2023-08-13 |
human |
| Mitch Earleywine, Fiona Low, Brianna R Altman, Joseph De Le. How Important Is a Guide Who Has Taken Psilocybin in Psilocybin-Assisted Therapy for Depression? Journal of psychoactive drugs. 2022-03-23. PMID:35318904. |
importance ratings for guides who had used psilocybin significantly exceeded the "somewhat important" level (50 on a 0-100 scale), other guide-related qualities, and comparable ratings for a cognitive behavioral therapist who shared demographics, had experience with depression and received cognitive therapy personally. |
2022-03-23 |
2023-08-13 |
human |
| Agnieszka D Sekula, Luke Downey, Prashanth Puspanatha. Virtual Reality as a Moderator of Psychedelic-Assisted Psychotherapy. Frontiers in psychology. vol 13. 2022-03-21. PMID:35310225. |
psychotherapy with the use of psychedelic substances, including psilocybin, lysergic acid diethylamide (lsd), ketamine, and 3,4-methylenedioxymethamphetamine (mdma), has demonstrated promise in treatment of post-traumatic stress disorder (ptsd), anxiety, addiction, and treatment-resistant depression. |
2022-03-21 |
2023-08-13 |
human |
| Tristan D McClure-Begley, Bryan L Rot. The promises and perils of psychedelic pharmacology for psychiatry. Nature reviews. Drug discovery. 2022-03-18. PMID:35301459. |
notably, phase ii trials have shown that psilocybin can produce statistically significant clinical effects following one or two administrations in depression and anxiety. |
2022-03-18 |
2023-08-13 |
Not clear |
| Shawn Ziff, Benjamin Stern, Gregory Lewis, Maliha Majeed, Vasavi Rakesh Gorantl. Analysis of Psilocybin-Assisted Therapy in Medicine: A Narrative Review. Cureus. vol 14. issue 2. 2022-03-11. PMID:35273885. |
studies conducted with patients with advanced-stage cancer have demonstrated that psilocybin may also be beneficial at reducing depression and anxiety associated with psychological crises due to a terminal diagnosis. |
2022-03-11 |
2023-08-13 |
Not clear |
| Nicole Bates, Jennifer K Bello, Nosayaba Osazuwa-Peters, Mark D Sullivan, Jeffrey F Scherre. Depression and Long-Term Prescription Opioid Use and Opioid Use Disorder: Implications for Pain Management in Cancer. Current treatment options in oncology. 2022-03-07. PMID:35254595. |
existing evidence is inadequate to definitively recommend methylphenidate or novel agents, such as ketamine or psilocybin, as adjunctive treatments for cancer-related depression and pain. |
2022-03-07 |
2023-08-13 |
Not clear |
| Andrew Troy Hodge, Suporn Sukpraprut-Braaten, Matthew Narlesky, Robert C Strayha. The Use of Psilocybin in the Treatment of Psychiatric Disorders with Attention to Relative Safety Profile: A Systematic Review. Journal of psychoactive drugs. 2022-02-28. PMID:35225726. |
oral psilocybin is showing itself to be clinically efficacious by producing statistically significant reductions in depression and anxiety symptoms over time versus control in multiple clinical trials. |
2022-02-28 |
2023-08-13 |
Not clear |
| Robert B Kargbo, Alexander M Sherwood, Poncho Meisenheimer, Kelsey Lenoch, Solomon Abeb. Psilocybin: Characterization of the Metastable Zone Width (MSZW), Control of Anhydrous Polymorphs, and Particle Size Distribution (PSD). ACS omega. vol 7. issue 6. 2022-02-21. PMID:35187358. |
psilocybin, a serotonergic agonist, was granted a "breakthrough therapy" status by the food and drug administration for clinical trials involving major depressive disorder and treatment-resistant depression. |
2022-02-21 |
2023-08-13 |
Not clear |
| Jurriaan F M Strou. [Psilocybin compared with escitalopram for depression]. Nederlands tijdschrift voor geneeskunde. vol 166. 2022-02-09. PMID:35138714. |
[psilocybin compared with escitalopram for depression]. |
2022-02-09 |
2023-08-13 |
Not clear |
| Jurriaan F M Strou. [Psilocybin compared with escitalopram for depression]. Nederlands tijdschrift voor geneeskunde. vol 166. 2022-02-09. PMID:35138714. |
performed a study in which they compared psilocybin in combination with psychotherapy to escitalopram in combination with psychotherapy for depression. |
2022-02-09 |
2023-08-13 |
Not clear |
| Henry J Whitfiel. A Spectrum of Selves Reinforced in Multilevel Coherence: A Contextual Behavioural Response to the Challenges of Psychedelic-Assisted Therapy Development. Frontiers in psychiatry. vol 12. 2021-12-24. PMID:34950063. |
psychedelic-assisted therapy research for depression and ptsd has been fast tracked in the united states with the food and drugs administration (fda) granting breakthrough designations for mdma (post-traumatic stress disorder) and psilocybin (major depressive disorder). |
2021-12-24 |
2023-08-13 |
Not clear |
| Craig Pearson, Joshua Siegel, Jessica A Gol. Psilocybin-assisted psychotherapy for depression: Emerging research on a psychedelic compound with a rich history. Journal of the neurological sciences. vol 434. 2021-12-23. PMID:34942586. |
this review provides a comprehensive look at the potential use of psilocybin in the treatment of depression and trd. |
2021-12-23 |
2023-08-13 |
Not clear |
| Craig Pearson, Joshua Siegel, Jessica A Gol. Psilocybin-assisted psychotherapy for depression: Emerging research on a psychedelic compound with a rich history. Journal of the neurological sciences. vol 434. 2021-12-23. PMID:34942586. |
it includes an overview of the history, pharmacology, and proposed mechanism of psilocybin, and describes several published studies in the last decade which have provided evidence of the efficacy and safety of psilocybin-assisted psychotherapy for individuals with depression. |
2021-12-23 |
2023-08-13 |
Not clear |
| Gabrielle Agin-Liebes, Alan K Davi. Psilocybin for the Treatment of Depression: A Promising New Pharmacotherapy Approach. Current topics in behavioral neurosciences. 2021-11-23. PMID:34811715. |
psilocybin for the treatment of depression: a promising new pharmacotherapy approach. |
2021-11-23 |
2023-08-13 |
human |
| Gabrielle Agin-Liebes, Alan K Davi. Psilocybin for the Treatment of Depression: A Promising New Pharmacotherapy Approach. Current topics in behavioral neurosciences. 2021-11-23. PMID:34811715. |
several lines of evidence from early-phase experimental trials suggest that serotonergic psychedelics, particularly psilocybin, with therapeutic support show great promise in the treatment of depression with large effect sizes. |
2021-11-23 |
2023-08-13 |
human |
| Gabrielle Agin-Liebes, Alan K Davi. Psilocybin for the Treatment of Depression: A Promising New Pharmacotherapy Approach. Current topics in behavioral neurosciences. 2021-11-23. PMID:34811715. |
this chapter reviews the methods and findings from three small human laboratory clinical trials examining the effects of psilocybin therapy for patients with major depressive disorder and treatment-resistant depression. |
2021-11-23 |
2023-08-13 |
human |